Bangalore-based biotech company Biocon Ltd revealed that it will be joining hands with CytoSorbents Corporation that will see it gain exclusive commercialization rights for its sepsis treatment therapy, CytoSorb in India and other emerging markets.
Biocon Managing Director Kiran Mazumdar Shaw revealed that CytoSorb has been proved to be a 'first-in-class' therapy that is effective in treating sepsis patients.
While the financial details of the deal were not revealed, CytoSorbents Chief Executive Officer and President Phillip Chan said that the company will be helped by the strong regional sales and distribution network of Biocon in India.
"We are very pleased to enter into this initial agreement with Biocon to bring our potentially life-saving therapy to the people of India and other emerging markets. Unlike any other previous approach, CytoSorbattacks sepsis from multiple angles - reducing cytokine storm, reducing many deadly bacterial toxins, and directing immune cells to target the infection while avoiding damage to otherwise healthy organs. When combined with Biocon's critical care antibiotics, it is an ideal broad spectrum strategy to fight sepsis", Chan said.